...
首页> 外文期刊>Radiation oncology >Radiobiological restrictions and tolerance doses of repeated single-fraction hdr-irradiation of intersecting small liver volumes for recurrent hepatic metastases
【24h】

Radiobiological restrictions and tolerance doses of repeated single-fraction hdr-irradiation of intersecting small liver volumes for recurrent hepatic metastases

机译:交叉小肝体积反复单次hdr照射对复发性肝转移的放射生物学限制和耐受剂量

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background To assess radiobiological restrictions and tolerance doses as well as other toxic effects derived from repeated applications of single-fraction high dose rate irradiation of small liver volumes in clinical practice. Methods Twenty patients with liver metastases were treated repeatedly (2 - 4 times) at identical or intersecting locations by CT-guided interstitial brachytherapy with varying time intervals. Magnetic resonance imaging using the hepatocyte selective contrast media Gd-BOPTA was performed before and after treatment to determine the volume of hepatocyte function loss (called pseudolesion), and the last acquired MRI data set was merged with the dose distributions of all administered brachytherapies. We calculated the BED (biologically equivalent dose for a single dose d = 2 Gy) for different α/β values (2, 3, 10, 20, 100) based on the linear-quadratic model and estimated the tolerance dose for liver parenchyma D90 as the BED exposing 90% of the pseudolesion in MRI. Results The tolerance doses D90 after repeated brachytherapy sessions were found between 22 - 24 Gy and proved only slightly dependent on α/β in the clinically relevant range of α/β = 2 - 10 Gy. Variance analysis showed a significant dependency of D90 with respect to the intervals between the first irradiation and the MRI control (p < 0.05), and to the number of interventions. In addition, we observed a significant inverse correlation (p = 0.037) between D90 and the pseudolesion's volume. No symptoms of liver dysfunction or other toxic effects such as abscess formation occurred during the follow-up time, neither acute nor on the long-term. Conclusions Inactivation of liver parenchyma occurs at a BED of approx. 22 - 24 Gy corresponding to a single dose of ~10 Gy (α/β ~ 5 Gy). This tolerance dose is consistent with the large potential to treat oligotopic and/or recurrent liver metastases by CT-guided HDR brachytherapy without radiation-induced liver disease (RILD). Repeated small volume irradiation may be applied safely within the limits of this study.
机译:背景技术为了评估放射生物学的限制和耐受剂量,以及在临床实践中重复应用小肝体积的高剂量率单剂量高剂量照射所产生的其他毒性作用。方法20例肝转移患者在相同或相交的位置通过CT引导的间质近距离放射治疗以不同的时间间隔重复治疗(2-4次)。在治疗前后使用肝细胞选择性造影剂Gd-BOPTA进行磁共振成像,以确定肝细胞功能丧失的体积(称为假性病变),最后采集的MRI数据集与所有所给予的近距离放射治疗的剂量分布合并。我们基于线性二次模型计算了不同α/β值(2、3、10、20、100)的BED(单剂量d = 2 Gy的生物等效剂量),并估算了肝实质D90的耐受剂量因为BED在MRI中暴露了90%的假性病变。结果重复近距离放射治疗后的耐受剂量D90被发现在22-24 Gy之间,并且在临床相关的α/β= 2-10 Gy范围内仅轻微依赖于α/β。方差分析显示,D90与第一次照射和MRI对照之间的间隔(p <0.05)以及干预次数之间存在显着相关性。此外,我们观察到D90与假病变的体积之间存在显着的负相关(p = 0.037)。在随访期间,无论急性还是长期,均未出现肝功能障碍或其他毒性作用(如脓肿形成)的症状。结论肝实质的失活发生在大约BED的BED。 22-24 Gy对应于〜10 Gy的单次剂量(α/β〜5 Gy)。该耐受剂量与通过CT引导的HDR近距离放射治疗而无放射诱发性肝病(RILD)来治疗寡位和/或复发性肝转移的巨大潜力相符。可以在本研究范围内安全地重复使用小剂量照射。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号